RxDoctor Payments Data

Winston Ortiz, MD

Neurology · Tallahassee, FLNPI 1134196215

Payments from drug & device makers

$555,310in general payments, 2019–2025

Across 1,208 payments — averaging $459.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$411K
  • Eli Lilly$85K
  • AbbVie$20K
  • EMD Serono, Inc.$12K
  • Teva Pharmaceuticals USA, Inc.$6K
  • Greenwich Biosciences, Inc.$4K
  • plus $17K from 54 others

What the payments were for

  • Consulting fees$3,2585%
  • Speaking & faculty fees$30,70451%
  • Travel & lodging$1,8033%
  • Food & beverage$23,70840%
  • Education$3551%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis79$411,245
Eli Lilly2$85,424
AbbVie(2 entities)154$19,546
EMD Serono, Inc.58$12,354
Teva Pharmaceuticals USA, Inc.51$5,844
Greenwich Biosciences, Inc.39$3,688
AstraZeneca40$1,322
Jazz Pharmaceuticals Inc.54$1,274
Amgen(2 entities)60$1,226
SK Life Science, Inc.53$1,104
Lilly USA, LLC49$1,007
Biogen41$948
UCB, Inc.55$923
TG Therapeutics, Inc.15$797
Eisai Inc.37$767
Supernus Pharmaceuticals, Inc.74$681
Neurelis, Inc.33$672
Pfizer33$660
Genentech USA, Inc.29$571
Neurocrine Biosciences, Inc.13$446
Lundbeck LLC21$399
E.r. Squibb & Sons, L.L.C.9$394
Bristol Myers Squibb19$354
Otsuka America Pharmaceutical, Inc.7$318
Tanabe Pharma America, Inc.17$258
Argenx US, Inc.9$253
Catalyst Pharmaceuticals, Inc.12$229
Sunovion Pharmaceuticals Inc.22$217
Nevro Corp.5$207
Sanofi12$191
MDD US Operations, LLC6$178
Acadia Pharmaceuticals Inc11$175
CSL Behring8$147
Kyowa Kirin, Inc.8$130
Banner Life Sciences, LLC6$114
Genentech, Inc.1$105
Strongbridge US Inc.7$99
Adamas Pharmaceuticals, Inc.7$95
Axsome Therapeutics, Inc.4$94
GE HealthCare4$81
Biohaven Pharmaceutical Holding Company Ltd.5$80
Acorda Therapeutics, Inc3$55
Biohaven Pharmaceuticals, Inc.3$49
Arbor Pharmaceuticals, Inc.3$49
Grifols USA, LLC3$47
Takeda Pharmaceuticals U.S.A., Inc.2$47
Johnson & Johnson(2 entities)2$47
Akcea Therapeutics, Inc.2$43
Avion Pharmaceuticals2$40
Mallinckrodt Hospital Products Inc.2$40
Merz Pharmaceuticals, LLC2$37
Mallinckrodt Enterprises LLC2$26
Merz North America, Inc.1$23
Upsher-smith Laboratories LLC1$22
Medtronic1$21
Livanova USA, Inc.1$21
Alnylam Pharmaceuticals Inc.1$20
Harmony Biosciences LLC1$14
Azurity Pharmaceuticals, Inc.1$14
Merck1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$555,310 in reported general payments places this provider in the 90th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$220,632
Medicare patients
237
Services billed
22,630

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SkyclarysOmaveloxolone13$405,402
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5026$272,544
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5022$245,380
CopaxoneGlatiramer Acetate22$161,976
BotoxOnabotulinumtoxina103$140,203
UbrelvyUbrogepant90$125,336
TecfideraDimethyl Fumarate14$124,990
Avonex (4 Pack)Interferon Beta-1a12$92,376
Nurtec OdtRimegepant Sulfate56$90,386
Emgality PenGalcanezumab-Gnlm85$67,958
Aimovig AutoinjectorErenumab-Aooe70$59,775
FycompaPerampanel27$33,999
XcopriCenobamate29$24,155
QuliptaAtogepant17$20,456
Lacosamide148$16,859

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenSkyclarys, Tecfidera, Avonex (4 Pack)$948$622,76739 claims
AbbVieBotox, Ubrelvy, Qulipta$19,546$285,996210 claims
CSL BehringPrivigen$147$245,38022 claims
Teva Pharmaceuticals USA, Inc.Copaxone$5,844$161,97622 claims
PfizerNurtec Odt$660$90,38656 claims
Eisai Inc.Fycompa$767$33,99927 claims
SK Life Science, Inc.Xcopri$1,104$24,15529 claims
Lilly USA, LLCReyvow$1,007$11,69414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,434 neurology providers in Florida.

Other neurology in Tallahassee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →